Phase 1 Small Cell Lung Carcinoma Clinical Trials

12 recruitingPhase 1

What is a Phase 1 trial?

Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.

Showing 112 of 12 trials

Recruiting
Phase 1Phase 2

PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56

Small Cell Lung CancerSmall Cell Lung Carcinoma
Memorial Sloan Kettering Cancer Center53 enrolled1 locationNCT04199741
Recruiting
Phase 1Phase 2

A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors

Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma
MediLink Therapeutics (Suzhou) Co., Ltd.118 enrolled22 locationsNCT07407933
Recruiting
Phase 1

A Study of LY4175408 in Participants With Advanced Cancer

Triple-Negative Breast CancerCarcinoma, Non-Small Cell LungNeoplasm Metastasis+2 more
Eli Lilly and Company240 enrolled27 locationsNCT07046923
Recruiting
Phase 1

A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3

Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3
Boehringer Ingelheim300 enrolled12 locationsNCT04429087
Recruiting
Phase 1Phase 2

Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)

Small Cell Lung Carcinoma
Merck Sharp & Dohme LLC110 enrolled48 locationsNCT04938817
Recruiting
Phase 1

A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer

Small Cell Lung Carcinoma (SCLC)Neuroendocrine Neoplasms
Boehringer Ingelheim12 enrolled1 locationNCT05963867
Recruiting
Phase 1

Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

Large Cell Neuroendocrine Carcinoma of the LungSmall Cell Lung CarcinomaNeuroendocrine Prostate Cancer+1 more
Novartis Pharmaceuticals116 enrolled6 locationsNCT07006727
Recruiting
Phase 1

A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

Carcinoma, Non-Small Cell LungGastroesophageal Junction AdenocarcinomaStomach Neoplasms+3 more
Seagen, a wholly owned subsidiary of Pfizer914 enrolled44 locationsNCT06131840
Recruiting
Phase 1

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

Triple-Negative Breast CancerGastric CancerOvarian Cancer+25 more
NiKang Therapeutics, Inc.150 enrolled19 locationsNCT06586957
Recruiting
Phase 1Phase 2

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Breast CancerTriple-Negative Breast CancerColorectal, Cancer+26 more
PMV Pharmaceuticals, Inc300 enrolled76 locationsNCT04585750
Recruiting
Phase 1Phase 2

Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)

Small Cell Lung CancerSmall Cell Lung Carcinoma
Washington University School of Medicine42 enrolled1 locationNCT07155200
Recruiting
Phase 1

Safety, Pharmacokinetics and Preliminary Efficacy of CS231295 in Advanced Solid Tumors

NeoplasmsSmall Cell Lung Carcinoma (SCLC)Glioblastoma, Adult
Chipscreen Biosciences, Ltd.102 enrolled2 locationsNCT06902350